Autologous T cell therapy - PersImmune

Drug Profile

Autologous T cell therapy - PersImmune

Alternative Names: PACTN - PerSImmune

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PersImmune
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Myelodysplastic syndromes

Most Recent Events

  • 18 Aug 2017 Preclinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV)
  • 18 Aug 2017 PersImmune in collaboration with University of California plans a phase I trial in Myelodysplastic syndromes (Second-line therapy or greater) in USA (NCT03258359)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top